ECHO

Watch now

The ECHO M.A.P. Programme

The ECHO M.A.P. (Maximising Advances in Phenylketonuria) programme links specialist hubs with local hospitals to support the best-practice care for PKU patients. Watch the on-demand ECHO M.A.P clinical site readiness training webinars to support the implementation of pegvaliase in your clinic.

Time: 8:00
Veeva code: EUCAN-PAL-00174

Watch now

ECHO

Watch

Changing the treatment landscape for adult PKU

Webinar 1 is presented by Prof Ania Muntau and focuses on how pegvaliase works and the clinical data behind the pegvaliase indication.
The following topics are covered:

• The European indication for pegvaliase
• The mode of action of pegvaliase
• The efficacy of pegvaliase in adults with PKU, as demonstrated in the phase 3 clinical trials PRISM-1 and PRISM-2
• A summary of the safety profile of pegvaliase in adults with PKU from PRISM-1 and PRISM-2
• Data from the PRISM studies that demonstrate the potential immunogenic effects of pegvaliase

Time: 08:00
Veeva code: EUCAN-PAL-00106

Watch

ECHO

Watch

SmPC guidelines on pegvaliase dosing

In webinar 2 Dr Mathias Woidy presents essential information from the European SmPC on pegvaliase dosing and considerations required for the administration of pegvaliase.
The following topics are covered:

• Available pegvaliase syringes
• Recommended dosing regimen
• Key considerations for pegvaliase treatment​ including blood Phe monitoring, use of premedication and adrenaline injection device, dietary Phe intake and training of patient and observer

Time: 10:00
Veeva code: EUCAN-PAL-00175

Watch

ECHO

Watch

Prescribing pegvaliase: Practicalities and considerations

Webinar 3 presented by Prof Ania Muntau, focusses on patient selection, prescription requirements and risk mitigation strategies required for pegvaliase treatment.
The following topics are covered:

• Pegvaliase pharmaceutical particulars
• Candidates for pegvaliase
• Prescription requirements and considerations prior to first dose
• Risk mitigation strategies associated with pegvaliase treatment
• Pegvaliase education packages

Time: 23:00
Veeva code: EUCAN-PAL-00176

Watch

ECHO

Watch

23:56

Patient communication for optimal care ​

Webinar 4 is presented by Pia Mause and focusses on patient communication and support during each phase of pegvaliase treatment and how to manage patient expectations.
The following topics are covered:

• The PKU Patient Support Program
• Role of the field nurse in pegvaliase treatment​
• The importance of communication with the patient and managing patient expectations​
• Patient support at each phase of pegvaliase treatment

Time: 24:00
Veeva code: EUCAN-PAL-00177

Watch

ECHO

Watch

An individualised approach: Pegvaliase administration ​

In webinar 5 Dr Mathias Woidy presents information on how to individualise dosing regimens, including when and how to modify pegvaliase dosing.
The following topics are covered:

• Proper administration of pegvaliase
• Modifying the dosing regimen in cases of hypersensitivity reactions, dose interruption, and hypophenylalaninaemia​
• Reconsidering pegvaliase treatment if there is no response by 18 months

Time: 16:00
Veeva code: EUCAN-PAL-00178

Watch

ECHO

Watch

Avoiding, identifying, and managing adverse events ​

Webinar 6 presented by Dr Aloisa Kohl, focusses on adverse events associated with pegvaliase and their management.
The following topics are covered:

• Adverse events associated with pegvaliase
• Identification of adverse events, including likely incidence, approximate time of onset and duration
• Management strategies for the adverse events​
• How and where to report adverse events

Time: 09:00
Veeva code: EUCAN-PAL-00179

Watch

ECHO

Watch

28:35

ECHO M.A.P. Webinar 7 – The dietician’s role during pegvaliase treatment ​

Webinar 7 presented by Christian Kogelmann, focusses on the effects of pegvaliase on dietary protein intake and provides insight on adjusting dietary protein in patients taking pegvaliase.
The following topics are covered:

• Effect of pegvaliase on dietary protein intake: data from clinical trials​
• The dietician’s role during pegvaliase treatment​
• When to adjust dietary protein and importance of maintaining diet during titration phase​
• Changing dietary behaviour in patients taking pegvaliase​
• Managing patient’s expectations

Time: 28:00
Veeva code: EUCAN-PAL-00180

Watch

ECHO

Watch

Use of pegvaliase in special populations ​

In webinar 8 Dr Aloisa Kohl provides guidance from the European SmPC on the use of pegvaliase in special populations.
The following topics are covered:

• The paediatric population​
• The use of pegvaliase during pregnancy and breast feeding, and its potential effects on fertility​
• The impact of pegvaliase on everyday activities (e.g., driving)​

Time: 05:00
Veeva code: EUCAN-PAL-00181

Watch

ECHO

Watch

Setting up a pegvaliase clinic the hub experience

Webinar 9 provides insight into setting up a pegvaliase clinic, Prof Ania Muntau shares UKE’s experience of treating patients with pegvaliase.
The following topics are covered:

• Preparing a pegvaliase clinic
• Patient selection
• Visit schedule and clinical routine
• Adverse event management
• Key learnings after two-years of using pegvaliase in the clinic

Time: 45:00
Veeva code: EUCAN-PAL-00182

Watch